Cerebrospinal Fluid Biomarkers for Parkinson Disease Diagnosis and Progression
Identifieur interne : 000215 ( Pmc/Corpus ); précédent : 000214; suivant : 000216Cerebrospinal Fluid Biomarkers for Parkinson Disease Diagnosis and Progression
Auteurs : Min Shi ; Joshua Bradner ; Aneeka Hancock ; Kathryn Chung ; Joseph Quinn ; Elaine Peskind ; Douglas Galasko ; Joseph Jankovic ; Cyrus Zabetian ; Hojoong Kim ; James Leverenz ; Thomas Montine ; Carmen Ginghina ; Un Kang ; Kevin Cain ; Yu Wang ; Jan Aasly ; David Goldstein ; Jing ZhangSource :
- Annals of neurology [ 0364-5134 ] ; 2011.
Abstract
There is a clear need to develop biomarkers for Parkinson disease (PD) diagnosis, differential diagnosis of parkinsonian disorders, and monitoring disease progression. We and others have demonstrated that a decrease in DJ-1 and/or α-synuclein in the cerebrospinal fluid (CSF) is a potential index for PD diagnosis, but not for PD severity.
Using highly sensitive and quantitative Luminex assays, we measured total tau, phosphorylated tau, amyloid beta peptide 1-42 (Aβ1-42), Flt3 ligand and fractalkine levels in CSF in a large cohort of PD patients at different stages as well as healthy and diseased controls. The utility of these five markers was evaluated for disease diagnosis and severity/progression correlation alone, as well as in combination with DJ-1 and α-synuclein. The major results were further validated in an independent cohort of cross-sectional PD patients as well as in PD cases with CSF samples collected longitudinally.
The results demonstrated that combinations of these biomarkers could differentiate PD patients not only from normal controls but also from patients with Alzheimer disease and multiple system atrophy. Particularly, with CSF Flt3 ligand, PD could be clearly differentiated from multiple system atrophy, a disease that overlaps with PD clinically, with excellent sensitivity (99%) and specificity (95%). In addition, we identified CSF fractalkine/Aβ1-42 that positively correlated with PD severity in cross-sectional samples as well as with PD progression in longitudinal samples.
We have demonstrated that this panel of seven CSF proteins could aid in PD diagnosis, differential diagnosis, and correlation with disease severity and progression.
Url:
DOI: 10.1002/ana.22311
PubMed: 21400565
PubMed Central: 3117674
Links to Exploration step
PMC:3117674***** Acces problem to record *****\Le document en format XML
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000215 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000215 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= JankovicV1 |flux= Pmc |étape= Corpus |type= RBID |clé= PMC:3117674 |texte= Cerebrospinal Fluid Biomarkers for Parkinson Disease Diagnosis and Progression }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:21400565" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a JankovicV1
![]() | This area was generated with Dilib version V0.6.19. | ![]() |